POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

FDA issues emergency use authorization for first U.S. coronavirus vaccine

Christian Fernsby |
The U.S. Food and Drug Administration (FDA) Friday issued authorization for emergency use of the first coronavirus vaccine in the United States.

Article continues below



Topics: U.S.   

The first Emergency Use Authorization (EUA) was issued to the coronavirus vaccine of American drugmaker Pfizer in partnership with German company BioNTech, allowing the vaccine to be distributed in the United States.

The FDA has determined that Pfizer-BioNTech coronavirus vaccine has met the statutory criteria for issuance of an EUA. The totality of the available data provides clear evidence that Pfizer-BioNTech coronavirus vaccine may be effective in preventing coronavirus, said the FDA in a statement.

The data also show that the known and potential benefits outweigh the known and potential risks, supporting the vaccine's use in millions of people 16 years of age and older, said the FDA.

"The FDA's authorization for emergency use of the first coronavirus vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world," said FDA Commissioner Stephen Hahn.

"Today's action follows an open and transparent review process that included input from independent scientific and public health experts and a thorough evaluation by the agency's career scientists to ensure this vaccine met FDA's rigorous, scientific standards for safety, effectiveness, and manufacturing quality needed to support emergency use authorization," he said in a statement.

The Pfizer-BioNTech vaccine contains a small piece of the SARS-CoV-2 virus's mRNA that instructs cells in the body to make the virus's distinctive "spike" protein.

When a person receives this vaccine, their body produces copies of the spike protein, which does not cause disease, but triggers the immune system to learn to react defensively, producing an immune response against SARS-CoV-2.

The vaccine is administered as a series of two doses, three weeks apart.

Global coronavirus cases surpassed 70 million on Friday, according to the Center for Systems Science and Engineering at Johns Hopkins University. The United States reported the most cases and deaths around the world as of 4:28 p.m. local time (2128 GMT), numbering 15,758,661 and 293,785, respectively.


What to read next

Dramatic increase in e-cigarette use among youth in U.S.
FDA's Marks: It deeply concerns us when we see preventable diseases reemerging
FDA Commissioner Scott Gottlieb on launch of The Real Cost youth e-cigarette prevention campaign